Valeant's Return To Deal-Making Pays Off For This Firm
Valeant Pharmaceuticals International Inc. dipped back into deal-making in a big way Sunday with a $10.1 billion plan to acquire Salix Pharmaceuticals Ltd., proving Valeant's still a cash-cow client for longtime...To view the full article, register now.
Already a subscriber? Click here to view full article